[A23-51] Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V
Last updated 15.09.2023
Project no.:
A23-51
Commission:
Commission awarded on 05.06.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Indication:
Adult patients with active moderate to severe hidradenitis suppurativa (acne inversa) with an inadequate response to conventional systemic therapy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.